Oxford Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Oxford Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$73K	Sell	34,709 -125,064	-78%	-$508K	0.01%	158
2019 Q4	$869K	Buy	159,773 +36,064	+29%	+$126K	0.02%	949
2019 Q3	$372K	Buy	123,709 +29,013	+31%	+$122K	0.01%	1375
2019 Q2	$354K	Buy	94,696 +6,663	+8%	+$26.1K	0.01%	1407
2019 Q1	$354K	Sell	88,033 -4,568	-5%	-$19.3K	0.01%	1365
2018 Q4	$340K	Buy	92,601 +28,665	+45%	+$195K	0.01%	1350
2018 Q3	$550K	Buy	63,936 +8,902	+16%	+$89K	0.01%	1282
2018 Q2	$607K	Buy	55,034 +1,682	+3%	+$18.8K	0.01%	1265
2018 Q1	$615K	Buy	53,352 +29,523	+124%	+$279K	0.01%	1159
2017 Q4	$256K	Buy	+23,829	New	+$305K	0.01%	1381
2017 Q2	–	Sell	-13,809	Closed	-$287K	–	1508
2017 Q1	$287K	Buy	+13,809	New	+$216K	0.01%	1210

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Oxford Asset Management's CRVS Position: Q1 2020 in Review

Oxford Asset Management reduced its Corvus Pharmaceuticals (CRVS) stake by 78% in Q1 2020, selling an estimated $508K and leaving 34,709 shares worth $73K. The position accounts for 0.01% of the portfolio, ranked #158.

Oxford Asset Management first reported a position in CRVS in Q1 2017 and has held it in 11 quarters since. The position peaked at $869K in Q4 2019. 43 funds tracked by Wall St. Rank hold CRVS as of Q1 2020.

Oxford Asset Management held 34,709 shares of Corvus Pharmaceuticals worth $73K as of Q1 2020.
Oxford Asset Management sold 125,064 Corvus Pharmaceuticals shares in Q1 2020, an estimated $508K.
Corvus Pharmaceuticals made up 0.01% of Oxford Asset Management's portfolio in Q1 2020, its #158 holding.
Oxford Asset Management first reported a position in Corvus Pharmaceuticals in Q1 2017 and has held it in 11 quarters since.
Oxford Asset Management's Corvus Pharmaceuticals position peaked at $869K in Q4 2019.
43 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.